Phalanx Aromasin / Exemestane 25mg

Description

Phalanx Aromasin delivers 25mg of Exemestane — the suicidal aromatase inhibitor that permanently binds and deactivates the aromatase enzyme rather than competing with it reversibly. This mechanism makes Exemestane fundamentally different from Anastrozole and Letrozole: once it inactivates an aromatase molecule, that molecule is gone. Oestrogen suppression is durable, rebound is blunted, and the risk of oestrogen flare on discontinuation is significantly reduced. At 25mg — the standard clinical dose — Exemestane delivers approximately 85% aromatase inhibition. Its steroidal backbone also provides mild androgenic activity, which is clinically relevant for preserving bone mineral density and may offer minor anabolic signalling. For post-cycle therapy, Exemestane is the preferred AI over anastrozole and letrozole: it doesn’t negatively impact lipid profiles to the same degree, its effects on HDL are milder, and the suicidal mechanism ensures oestrogen doesn’t spike when you stop. Independently verified at 99%+ purity by Puralytix. For PCT use, Exemestane 12.5–25mg every other day is the typical protocol — preventing oestrogen rebound as endogenous testosterone begins recovering without crashing oestradiol to levels that impair mood and sexual function. Its steroidal backbone means Exemestane also contributes marginally to bone mineral density protection, a meaningful long-term consideration for athletes running multiple cycles annually.